These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 16040330)

  • 1. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
    Hasegawa M
    J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.
    Sakkas LI; Chikanza IC; Platsoucas CD
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological basis of systemic sclerosis.
    Zuber JP; Spertini F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii23-5. PubMed ID: 16987826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
    Fuschiotti P; Medsger TA; Morel PA
    Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
    Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
    Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunobiology of systemic sclerosis.
    Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
    Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis.
    Chizzolini C
    Curr Opin Rheumatol; 2008 Nov; 20(6):707-12. PubMed ID: 18946333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential roles of interleukin-17A in the development of skin fibrosis in mice.
    Okamoto Y; Hasegawa M; Matsushita T; Hamaguchi Y; Huu DL; Iwakura Y; Fujimoto M; Takehara K
    Arthritis Rheum; 2012 Nov; 64(11):3726-35. PubMed ID: 22833167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of systemic scleroderma: immunological aspects].
    Mouthon L; García De La Peña-Lefebvre P; Chanseaud Y; Tamby MC; Boissier MC; Guillevin L
    Ann Med Interne (Paris); 2002 May; 153(3):167-78. PubMed ID: 12218899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of systemic sclerosis-current concept and emerging treatments.
    Furue M; Mitoma C; Mitoma H; Tsuji G; Chiba T; Nakahara T; Uchi H; Kadono T
    Immunol Res; 2017 Aug; 65(4):790-797. PubMed ID: 28488090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic aspects of scleroderma.
    Needleman BW
    Curr Opin Rheumatol; 1992 Dec; 4(6):862-8. PubMed ID: 1457282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.